Abstract
With the increasing number of paediatric cancer patients and with their prolonged survival, the evidence of a number of serious complications induced by anticancer therapy is rising. Osteonecrosis (ON) of bone is one of these treatment-related effects with a multifactorial pathogenesis. In the past few years, several polymorphisms of candidate genes with possible role in development of this disorder were studied.We summarized potential risk factors leading to increased susceptibility to osteonecrosis of bone development in cancer patients during childhood and to present current knowledge in the field of genetic aspects of this condition (Ref. 86).
Keywords:
anticancer treatment; avascular necrosis; corticosteroids; genetic determinants.; osteonecrosis; transplantation.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adrenal Cortex Hormones / adverse effects
-
Antineoplastic Agents / adverse effects
-
Catalase / genetics
-
Child
-
Genetic Predisposition to Disease
-
Graft vs Host Disease / complications
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / genetics*
-
Neoplasms / complications
-
Neoplasms / therapy*
-
Nitric Oxide Synthase / genetics
-
Osteonecrosis / etiology
-
Osteonecrosis / genetics*
-
Plasminogen Activator Inhibitor 1 / genetics*
-
Radiotherapy / adverse effects
-
Risk Factors
-
Vascular Endothelial Growth Factor A / genetics*
Substances
-
Adrenal Cortex Hormones
-
Antineoplastic Agents
-
HIF1A protein, human
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Plasminogen Activator Inhibitor 1
-
SERPINE1 protein, human
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Catalase
-
Nitric Oxide Synthase